Samarth Kulkarni Sells 18,360 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Samarth Kulkarni also recently made the following trade(s):

• On Monday, December 2nd, Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $55.10, for a total value of $826,500.00.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP opened at $47.91 on Friday. The company has a market capitalization of $4.11 billion, a P/E ratio of -10.96 and a beta of 1.67. The business has a fifty day simple moving average of $42.25 and a two-hundred day simple moving average of $46.04. CRISPR Therapeutics AG has a 1 year low of $36.52 and a 1 year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Bank of America cut their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a report on Thursday, February 13th. Chardan Capital lowered their price target on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a research report on Wednesday. Finally, Truist Financial increased their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and an average target price of $74.40.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Highline Wealth Partners LLC purchased a new position in shares of CRISPR Therapeutics during the 4th quarter valued at $39,000. Western Pacific Wealth Management LP lifted its position in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after buying an additional 500 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of CRISPR Therapeutics during the 3rd quarter valued at $40,000. Darwin Wealth Management LLC purchased a new position in shares of CRISPR Therapeutics during the 3rd quarter valued at $43,000. Finally, Eastern Bank purchased a new position in shares of CRISPR Therapeutics during the 3rd quarter valued at $70,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.